NFORMATION DISCLOSURE CITATION (Use several sheets if necessary)   Name   Class   Subclass   Filiag Date   November 17, 2003   1624									_										
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)  U.S. PATENT DOCUMENTS  Subclass  Piling Date HAPpropriate (Info Info Info Info Info Info Info Info		Dodoná su J T													i i				
November 17, 2003   1624   1	1	EA	1																
Document Number	(Use several sheets if necessary)												ION						
Document Number	4 7000												November 17, 2003 16						
FOREIGN PATENT DOCUMENTS   FOREIGN PATENT	U.S. PATENT DOCUMENTS													- <sub>T</sub>	<del>.</del>				
FOREIGN PATENT DOCUMENTS	ŀ	Examile Control	7/	Document Number					er			Date	Name	Class	Subclass				
Document Number   Date   Country   Class   Subclass   Translation   Yes   No   The process   No   No   No   No   No   No   No	ľ	71.N./		1								3/16/04	Allen et al.		<del>-</del>	Питерио	priate		
Document Number   Date   Country   Class   Subclass   Franslation   Yes   No	Ĺ	/T.N./		2	20	02	00	61	3	0	4	5/23/02	Miller et al.						
Document Number   Date   Country   Class   Subclass   Franslation   Yes   No   T.N.   10   0   3   6   3   2   5   2/10/98   Japan	I									<u> </u>	-		-						
Document Number   Date   Country   Class   Subclass   Franslation   Yes   No	ŀ	<u></u>	$\dashv$		_	├─	┢	┢		├									
Document Number   Date   Country   Class   Subclass   Franslation   Yes   No	ŀ		$\dashv$		<del> </del>		╁	╁╌	<del> </del>	<del> </del>						<del> </del>			
Document Number   Date   Country   Class   Subclass   Franslation   Yes   No	ľ																		
Document Number   Date   Country   Class   Subclass   Franslation   Yes   No	L																		
Yes   No   1.0   0   3   6   3   2   5   2/10/98   Japan					FOREIGN PATENT DOCUMENTS														
T.N.   10   0   3   6   3   2   5   2/10/98   Japan	l				Do	cum	ent	Nu	mbe	r		Date	Country	Class	Subclass	Translation			
T.N.   10 0 3 6 3 2 6 2/10/98 Iapan	l		Ì													Yes	No		
T.N.   6   9   7   3   8   9   8   3   10/23/97   PCT	ľ	/T	N	3			3		3	2	_		Japan						
T.N./  6 9 7 3 8 9 8 3 10/23/97 PCT  9 1 7 0 1 7 0 2 5 5 9/37/01 PGT  9 2 30 0 0 2 3 0 7 4 5/16/01 Czoch  17.N./  9 Driscoll D. et al., "Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 o Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abstracy only).  17.N./  18 Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression in Huma Pancreatic Cancer" (1998) American Journal of Pathology 153 (1): 213-222.  12 Liu N. et al., "Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Huma Pancreas and Pancreatic Carcinoma" (1998) American Journal of Pathology 153 (1): 263-269 .  13 Norris T., et al. "Discover of a new stable polymorph of 4 - (3-ethynylphenylamino) -6, 7-bis (2 methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form chang kinetics" J. Chem. Soc., Perkins Trans. 2 (2000) 12:2498-2502 .  14 Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediate Signal Transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" Proceedings of the Annual Meeting of the American Association for Cancer Research (1999) 29(2):739-748 (Abstract only SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8 Francois, I.  17.N./  18 Vatanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromaffi Cells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.  18 Voodburn J.R. et al., "D1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinic Development" (1997) XP-001009911 (Abstract only).  19 Authority American Science (1997) Pathology International 50:363-372.  19 Voodburn J.R. et al., "Overexpression of Keratinocyte Growth Factor Tyrosine Kinase Inhibitor Selected for Clinic Development" (1997) XP-001009911 (Abstract only).	Ļ	/ 1 .13	-/	4	10	0	3	6	3	_	6				<del> </del>	ļ			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  9 Driscoll D. et al., "Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 o Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abstractionly).  7T.N./ 10 Grunwald V. et al., (2003) REVIEW, J. Nat. Can. Inst., Vol. 95, No. 12, pp. 851-867.  11 Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression in Huma Pancreatic Cancer" (1998) American Journal of Pathology 153 (1): 213-222.  12 Liu N. et al., "Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Huma Pancreas and Pancreatic Carcinoma" (1998) American Journal of Pathology 153 (1): 263-269.  13 Norris T., et al. "Discover of a new stable polymorph of 4 - (3-ethynylphenylamino) -6, 7-bis (2 methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form chang kinetics" J. Chem. Soc., Perkins Trans. 2 (2000) 12:2498-2502.  14 Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediate Signal Transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" Proceedings of the Amnual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8. Francols, I.  17.N./ Watanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromafficells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.  17 Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).	Ť	/T.N./	0000000	650000000 K	0	7	3	χ 2	Q	72	3			000000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Driscoll D. et al., "Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 o Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abstraction)).  T.N./ 100 Grunwald V. et al., (2003) REVIEW, J. Nat. Can. Inst., Vol. 95, No. 12, pp. 851-867.  Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression in Huma Pancreatic Cancer" (1998) American Journal of Pathology 153 (1): 213-222.  Iz Liu N. et al., "Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Huma Pancreas and Pancreatic Carcinoma" (1998) American Journal of Pathology 153 (1): 263-269.  Norris T., et al. "Discover of a new stable polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2 methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form chang kinetics" J. Chem. Soc., Perkins Trans. 2 (2000) 12:2498-2502.  14 Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediate Signal Transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" Proceedings of the Annual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only)  15 SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8 . Francois, I  T.N./ Watanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromaffi Cells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.  17 Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).	Ļ	000000000000000000000000000000000000000		g	8	200000	9	·····	2	-5····	5			000000000000000000000000000000000000000			200000000000000000000000000000000000000		
Driscoll D. et al., "Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 of Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abstrationally).    T.N.   10   Grunwald V. et al., (2003) REVIEW, J. Nat. Can. Inst., Vol. 95, No. 12, pp. 851-867.     Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression in Huma Pancreatic Cancer" (1998) American Journal of Pathology 153 (1): 213-222.     Iz.   Liu N. et al., "Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Huma Pancreas and Pancreatic Carcinoma" (1998) American Journal of Pathology 153 (1) 263-269.     Id.   Norris T., et al. "Discover of a new stable polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form chang kinetics" J. Chem. Soc., Perkins Trans. 2 (2000) 12:2498-2502.     Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediate Signal Transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" Proceedings of the Amnual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only)     SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8. Francois, I.     Watanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromaffic Cells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.     Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).     EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	ļ	***************************************		<u> </u>	20.	<b>0</b>	0	3	<u> </u>	7	4	5/16/01:	Czech						
Driscoll D. et al., "Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 of Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abstrationally).    T.N.   10   Grunwald V. et al., (2003) REVIEW, J. Nat. Can. Inst., Vol. 95, No. 12, pp. 851-867.     Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression in Huma Pancreatic Cancer" (1998) American Journal of Pathology 153 (1): 213-222.     It is N. et al., "Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Huma Pancreas and Pancreatic Carcinoma" (1998) American Journal of Pathology 153 (1): 263-269.     It is Norris T., et al., "Discover of a new stable polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino)			$\Box$			Ľ.	L	ļ	<u> </u>			ļ	_						
Driscoll D. et al., "Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 of Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abstrationally).    T.N.   10   Grunwald V. et al., (2003) REVIEW, J. Nat. Can. Inst., Vol. 95, No. 12, pp. 851-867.     Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression in Huma Pancreatic Cancer" (1998) American Journal of Pathology 153 (1): 213-222.     It is N. et al., "Comparative Phenotypic Studies of Duct Epithelial Cell Lines Derived from Normal Huma Pancreas and Pancreatic Carcinoma" (1998) American Journal of Pathology 153 (1): 263-269.     It is Norris T., et al., "Discover of a new stable polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2)     In it is network the polymorph of 4 – (3-ethynylphenylamino)	ŀ							<u> </u>	<u> </u>		L		<u> </u>		<u> </u>	<u> </u>			
Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abstractionly).	ŀ		Driscoll D. et al., "Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor PD183805 Vascular Endothelial Growth Factor Secretion from Several Tumor Models" (1999) XP-001014746 (Abst												2005 00				
T.N.   10   Grunwald V. et al., (2003) REVIEW, J. Nat. Can. Inst., Vol. 95, No. 12, pp. 851-867															Abstract				
Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression in Huma Pancreatic Cancer" (1998) American Journal of Pathology 153 (1): 213-222.    Iz	ŀ	/T.N./10 Grunwald V. et al., (2003) REVIEW, J. Nat. Can. Inst., Vol. 95, No. 12, pp. 851-867.  Ishiwata T. et al., "Characterization of Keratinocyte Growth Factor and Receptor Expression is																	
12	ŀ												ssion in	Human					
Pancreas and Pancreatic Carcinoma" (1998) American Journal of Pathology 153 (1) 263-269  Norris T., et al. "Discover of a new stable polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2 methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form chang kinetics" J. Chem. Soc., Perkins Trans. 2 (2000) 12:2498-2502.  14 Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediate Signal Transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" Proceedings of the Annual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only International Society for Medicine Research (1999) 5(2):1-8. Francois, I.  T.N./ Watanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromaffic Cells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.  Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).  EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	L	/T.N./	<u> </u>																
Norris T., et al. "Discover of a new stable polymorph of 4 – (3-ethynylphenylamino) -6, 7-bis (2 methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form chang kinetics" J. Chem. Soc., Perkins Trans. 2 (2000) 12:2498-2502.  14 Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediate Signal Transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" Proceedings of the Annual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8. Francois, I.    T.N.																			
methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to monitor form chang kinetics" J. Chem. Soc., Perkins Trans. 2 (2000) 12:2498-2502.    14	ŀ	/ > .3 % ./	-																
Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediate Signal Transduction with CP-358774: Dynamics of receptor inhibition and anti-tumor effects" Proceedings of the Annual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8. Francois, I.  T.N./  16 Watanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromafficells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.  Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).  EXAMINER  /Tamthom Truong/  DATE CONSIDERED  *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	methoxyethoxy) quinazolinium methanesulfonate using near-infrared spectroscopy to										roscopy to moni	tor form	change						
the Annual Meeting of the American Association for Cancer Research (1999) 291(2):739-748 (Abstract only  SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8. Francois, I.  T.N./  16 Watanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromaffic Cells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.  17 Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).  EXAMINER    Tamthom Truong/   DATE CONSIDERED   08/11/2008	1			1	Pollack et al., "Therapy of Human Carcinomas in Athymic Mice by Inhibition of EGF Receptor-mediated														
SMR Committee: "Protein Kinases: Therapeutic Opportunities" The Newsletter for the Society for Medicine Research (1999) 5(2):1-8. Francois, I.   T.N./		/T.N./	1																
T.N.   Research (1999) 5(2):1-8. Francois, I.	ŀ		15																
Watanabe M. et al., "Overexpression of Keratinocyte Growth Factor in Cancer Cells and Enterochromafficells in Human Colorectal Cancer" (2000) Pathology International 50:363-372.  Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).  EXAMINER  /Tamthom Truong/  DATE CONSIDERED  *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	L	/T.N./ Research (1999) 5(2):1-8 Francois, I.																	
Woodburn J.R. et al., "ZD1839, An Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development" (1997) XP-001009911 (Abstract only).  EXAMINER  /Tamthom Truong/  DATE CONSIDERED  *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	F				Wat	anat	oe N	1. e	t al.	, "C	vere	expression of	Keratinocyte C	Growth Factor in Ca	ncer Cells and E	Enterochi	romaffin		
EXAMINER /Tamthom Truong/  DATE CONSIDERED  *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	ŀ		17		Jell:	s in	Hur urr 1	nan I P	Col	orec	tai (	ancer" (200 839 An Eni	u <i>) Pathology Ini</i> dermal Growth I	ernational 50:363-3 Factor Tyrosine Kin	14 • ase Inhibitor Sele	ected for	Clinical		
EXAMINER /Tamthom Truong/  *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	١	/T.N	//																
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in																			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	ŀ																		
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	ŀ		$\vdash$									<b></b>							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	ŀ		$\vdash$	$\dashv$															
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in	1	EXAMIN	VER				/Ta	ımt	hon	n Tı	uor	ıg/	DATE CO		08/11/2008				
														e with MPEP 609: Drav		on if not in	)		

Lined through references have no copy provided.

Applicants: Douglas J. M. Allen et al. Serial No.: 10/716,098

Filed: November 17, 2003

Exhibit A